期刊文献+

多西他赛诱导乳腺癌Bcap37细胞凋亡作用的研究 被引量:10

Apoptosis-inducing effect of docetaxel on the breast cancer cell line Bcap37
下载PDF
导出
摘要 目的:探讨多西他赛(≤10μmol/L)体外对人乳腺癌Bcap37细胞凋亡的作用及其机制。方法:采用琼脂糖凝胶电泳观察Bcap37细胞凋亡情况;原位末端标记(TUNEL)法测定Bcap37细胞凋亡指数(apoptoticindex,AI);流式细胞仪检测Bcap37细胞周期。结果:与对照组相比,实验组琼脂糖凝胶电泳显示凋亡特有的梯状图谱;实验组显示细胞核染成棕色的凋亡细胞,且AI较对照组显著增大,具有量效依赖性,P<0·001。实验组G2/M期细胞比例较对照组显著升高,G1、S期细胞比例显著降低,P<0·01。结论:多西他赛(≤10μmol/L)诱导人乳腺癌Bcap37细胞凋亡,细胞周期阻滞在G2/M期。 OBJECTIVE: To investigate the effect of docetaxel (≤10 μmol/L) on the apoptosis of breast cancer cell line Bcap37 in vitro and elucidate its possible mechanisms. METHODS: The apoptosis of breast cancer cell line Bcap37 was observed by agarose gel electrophoresis, the cell apoptotic index (AI) was evaluated by TUNEL and the cell cycle was detected by flow cytometry. RESULTS: Compared with the control group, DNA ladder was obtained with the agarose gel electrophoresis; apoptotic cell were dyed brown in cell nuclear and AI were increased and showed a dose-dependent effect, P〈0.001; the percent of G2/M-phase cell was elevated and the percent of G1-phase and S-phase cell were lower in docetaxel groups, P〈0.01. CONCLUSION: Docetaxel (≤10 μmol/L) might induce the apoptosis in breast cancer cell line Bcap37. Its mechanism probably was due to an arrest at G2/M-phases.
出处 《中华肿瘤防治杂志》 CAS 2006年第18期1384-1386,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤/药理学 乳腺肿瘤/病理学 紫杉酚/投药和剂量 肿瘤细胞 培养的 细胞凋亡 breast neoplasms/pharmacology breast neoplasms/patholgy paclitaxel/administration & dosage tumor cells, cultured apoptosis
  • 相关文献

参考文献10

  • 1Tabernero J, Climent M A, Lluch A, et al. Amulticentre, randomised phase II study of weekly or S-weekly docetaxel in patients with metastatic breast cancer[J]. Ann Oncol, 2004, 15(9): 1358-1365.
  • 2Ishikawa T, Shimizu S, Inaba M, et al. A Multieenter phase Ⅱ study of docetaxel 60 mg/m^2 first-line chemotherapy in patients with advanced or recurrent nreast cancer[J]. Breast Cancer,2004, 11(4): 374-379.
  • 3Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase Ⅱ multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer[J]. Br J Cancer,2004, 91(8): 1466-1471.
  • 4Mavroudis D, Malamos N, Polyzos A, et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenterphase II study[J]. Oncology,2004, 67(3-4): 250-256.
  • 5Gomez-Bernal A, Cruz J J, Olaverri A, et al. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer[J]. Anticancer Drugs, 2005,16 (1) : 77 - 82.
  • 6Park S H, Cho E K, Bang S M, et al. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment[J]. BMC Cancer,2005,22(5):21-21.
  • 7刘龙,刘璐,童冠圣,封国生,高宏,高文,李澄,刘志勇.^(32)P-磷酸铬体外诱导人非小细胞肺癌A549细胞凋亡[J].中华放射医学与防护杂志,2004,24(3):233-236. 被引量:2
  • 8Wolff A C, Davidson N E. Primary systemic therapy in operable breast cancer[J]. J Clin Oncol,2000,18(7) .1558-1569.
  • 9Diaz J F, Andreu J M. Assembly of purified GDP-tubulin into microtubules inducedby taxol and taxotere: reversibility, ligand stoichiometry, and competition [J]. Biochemistry, 1993, 32(11) : 2747- 2755.
  • 10Green D R, Reed J. Mitochondria and apoptosis[J]. Science,1998,281 (5381):1309-1312.

二级参考文献2

共引文献1

同被引文献90

引证文献10

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部